Alvespimycin

Solid Tumor

Bristol-Myers SquibbSmall moleculePhase 1Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 59/ 100

Competitive context

928 Active assets in the Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
Inno-206 The First Affiliated Hospital of Soochow University	Phase 2/3	BB
DINITROGEN MONOXIDE Medical College of Wisconsin	Phase 4	BB
Glycopyrrolate Medical College of Wisconsin	Phase 4	BB

View all 50 →

Same molecule, other indications

Alvespimycin is also rated in:

cancer of unknown primary siteDormant

CCC

Indicative ·

52 / 100

salivary gland adenoid cystic carcinomaDormant

CC

Indicative ·

47 / 100

Stage IV Adult Diffuse Small Cleaved Cell LymphomaDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.